The role of endocrine factors and markers of cellular stress in predicting the effectiveness of the treatment of climacteric syndrome in the period of perimenopause




menopause, perimenopausal period, climacteric syndrome, menopausal hormone therapy, HSP60, GroEl


Women of menopausal age make up 10% of the world's population, and the problem of pathological menopause remains relevant today. Estrogen deficiency is considered to be the cause of menopause, so the use of replacement therapy is a pathogenetically sound method. It is possible that the immune system also plays a role in shaping the clinical picture. There is a certain relationship between estrogen levels and markers of intracellular stress. Studying the level of heat shock proteins as proven factors of cellular stress, along with endocrine factors, can become a reliable marker for the prognosis, course and compensation of disorders of the neurovegetative state of women in this period of life.

Purpose - to study the role of levels of antimullerian, follicle-stimulating, luteinizing, thyroid-stimulating hormones, levels of antibodies (IgG) to human heat shock protein (Hsp60) and its bacterial homologue (Groel) in the prognosis, diagnosis and treatment of psychopathological manifestations in perimenopausal women.

Materials and methods. The study examined 158 patients with perimenopausal menopausal syndrome between October 2019 and March 2022. The patients were divided into two groups. The 1st (main) group included 80 patients who agreed to receive treatment according to the standard regimen (combined treatment in a cyclic regimen (estrogens + gestagens), and the 2nd (comparative) group included 78 women who refused the proposed treatment

Results. A decrease (p<0.001) in the risk of not achieving a high treatment effect was found for the main group, OR=0.12 (95% CI: 0.06-0.26) compared with the control group. It was found that a higher level of antibodies to GroEl, OR=0.989 (95% CI: 0.984-0.996), revealed a lower (p=0.001) risk of not achieving a high treatment effect. A higher body mass index (BMI) of a woman increases the risk of not achieving a high treatment effect (p<0.001), OR=1.19 (95% CI: 1.10-1.30) for every 1 kg/m2. When standardized by BMI, an integral indicator of psychopathological manifestations, taking into account the method of treatment and the level of antimullerian hormone, a decrease (p=0.039) in the risk of failure to achieve a high treatment effect was found for the main group, OR=0.16 (95% CI: 0.07-0.39) compared with the control group.

Conclusions. It has been established that the most informative indicator for predicting the effectiveness of treatment of women with psychopathological manifestations is antimüllerian hormone. The data also show that the determination of the level of antibodies to GroEl correlates with the success of treatment of women with psychopathological manifestations of menopausal syndrome.

The study was conducted in accordance with the principles of the Declaration of Helsinki. The study protocol was approved by the Local Ethics Committee of the institutions mentioned in the paper. Informed consent of women was obtained for the study.

No conflict of interests was declared by the authors.


Berestoviy V, Mahmood A, Venckivska I, Ginzburg V, Sokol I, Berestoviy O, Govsieiev D. (2021). The overview and role of heat shock proteins (HSP) especially HSP 60 and 70 in reproduction and other pathologies (a literature review). Медичні перспективи. 26 (1): 54-62.

De Villiers T, Tatarchuk T, Avramenko N, Bulavenko O, Gabal V, Burlaka O, Ganzhiy I, Genyk N, Hryshchenko O, Gromova A. (2016). National consensus on management of female patients in menopause. Reproductive endocrinology. 27: 8-25.

Dillon KE, Gracia CR. (2013). What is normal ovarian reserve? Seminars in reproductive medicine. 31 (6): 427-436.; PMid:24101223

Fait T. (2019). Menopause hormone therapy: latest developments and clinical practice. Drugs in context: 8.; PMid:30636965 PMCid:PMC6317580

Gallagher D et al. (1996). How Useful Is Body Mass Index for Comparison of Body Fatness across Age, Sex, and Ethnic Groups? Am J Epidemiol. 143 (3): 228-239.; PMid:8561156

Hall JE. (2015, Sep). Endocrinology of the Menopause. Endocrinol Metab Clin North Am. 44 (3): 485-496.; PMid:26316238 PMCid:PMC6983294

Kelsey TW, Wright P, Nelson SM, Anderson RA, Wallace WHB. (2011). A validated model of serum anti-müllerian hormone from conception to menopause. PloS one. 6 (7): e22024.; PMid:21789206 PMCid:PMC3137624

Makarenko M, Govsieiev D, Vorona R, Tsisarenko A, Vasil'tchuk O, Pavlyuk O et al. (2016). Identification and characterization of antibodies against human hsp60 at pregnancy. Health of woman. 8 (114): 75-75.

Partyka Ł, Hartwich J, Kieć-Wilk B, Polus A, Wybrańska I, Dembińska-Kieć A. (2001). Is atherosclerosis an autoimmunological process? Przeglad Lekarski. 58 (12): 1067-1070.

Rajtar-Ciosek A, Kacalska-Janssen O, Zmaczyński A, Wyroba J, Tomczyk R, Wiatr J et al. (2015). Reduction in the level of antibodies against heat shock proteins 60 during different hormonal protocols in postmenopausal women. Menopause Review/Przegląd Menopauzalny. 14 (4): 218-222.; PMid:26848292 PMCid:PMC4733899

Santoro N. (2017). Using Antimüllerian hormone to predict fertility. Jama. 318 (14): 1333-1334.; PMid:29049571

Sirotkin AV. (2011). Growth factors controlling ovarian functions. Journal of Cellular Physiology. 226 (9): 2222-2225.; PMid:21660945

The North American Menopause Society. (2017). The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 24 (7): 728-753.; PMid:28650869

Uint L, Gebara OC, Pinto LB et al. (2003). Hormone replacement therapy increases levels of antibodies against heat shock protein 65 and certain species of oxidized low density lipoprotein. Braz J Med Biol Res. 36: 491-494.; PMid:12700827